Quintiles blueprints new Shanghai R&D center in expansion drive

The multinational CRO Quintiles is stepping up its game in China's fast-growing drug development arena with plans to partner with a local clinical research group as it builds a new regional headquarters facility for itself in Shanghai. Quintiles has formed a partnership with the Shanghai Clinical Research Center, blueprinting a 43,000-square-foot complex that will house 450 staffers.

"By collaborating with SCRC in labs we can help local and international biopharma companies develop new and better medicines to serve China's enormous unmet medical needs," says Ling Zhen, Quintiles' general manager in China. Quintiles will invest $14 million establishing its new research center.

Quintiles has been operating in China for the past 15 years. And it's been growing its organization in the populous nation as drug developers from around the world turn their attention to one of the biggest emerging markets on the planet. The CRO set up Kun To, a local China CRO, last year and has facilities in Beijing, Dalian, and Hong Kong as well as Shanghai.

Shanghai Clinical Research Center's "staff and modern technology will be further enhanced through Quintiles' investments," says SCRC President Rongxing Gan. "We are delighted to work closely with Quintiles to further biopharma innovation and improve human health."

- here's the press release

Suggested Articles

Fifteen of the 22 patients in a gene therapy trial no longer needed transfusions, while the remainder needed fewer transfusions.

Argos Therapeutics is ending its kidney cancer trial and mulling options, including a merger or sale, to stay alive.

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.